17 hasil untuk "F. Angotzi"
Menampilkan 1–17 · 0,45 detik · RSS
-
Artikel Jurnal
DP047 | A SINGLE CENTER EXPERIENCE OF FIXED DURATION THERAPY IN 108 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Background. The current treatment strategies for patients (pts) with chronic lymphocytic leukemia (CLL) include a continuous BTK inhibitor (BTKi) or a fixed-duration therapy (FDT) with combinations of target agents (BTKi and/or venetoclax [VEN] and/or antiCD20 monoclonal antibodies [mAb]). However…
-
Artikel Jurnal
DP050 | ASSESSING THE IMPACT OF COMORBIDITIES IN HAIRY CELL LEUKEMIA: VALIDATION OF THE CLL-CI/TRES SCORE IN PATIENTS TREATED WITH PURINE ANALOGUES
Introduction Hairy cell leukemia (HCL) is an indolent disease that enjoys excellent response and durable remissions after therapy with the purine analogues (PAs) cladribine (2CDA) and pentostatin (DCF). Yet, the impact of different comorbidities on HCL outcomes is still unknown, and no standardized…
-
Artikel Jurnal
DP055 | DISTINCT RELAPSE PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA AFTER THERAPY WITH BTK OR BCL2 INHIBITORS
Introduction Bruton tyrosine kinase inhibitors (BTKi) and venetoclax exert their effect on two different populations of chronic lymphocytic leukemia (CLL) cells: while BTKi act on the dividing subpopulation of CLL cells, which is killed after mobilization from the lymph nodes into the circulation…
-
Artikel Jurnal
DP054 | INFECTIONS, SECOND PRIMARY MALIGNANCIES AND AUTOIMMUNE DISEASES IN MONOCLONAL B-CELL LYMPHOCYTOSIS AND EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM A RETROSPECTIVE COHORT OF A TERTIARY CARE CENTRE
Background. Monoclonal B-cell Lymphocytosis (MBL) is a premalignant phase of Chronic Lymphocytic Leukemia (CLL), defined by less than 5x10^9 clonal B-cells/L in the peripheral blood of otherwise healthy individuals. MBL is further classified into low-count (LC-MBL) (< 0.5x10^9 clonal B-cells/L) and…
-
Artikel Jurnal
DP025 | INDUCTION THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: INNOVATIONS IN THE ERA OF HYPOMETHYLATING AGENTS AND VENETOCLAX COMBINATION THERAPY
Background Prior to the approval of hypomethylating agents (HMAs) in combination with venetoclax (Ven) as first-line therapy for newly diagnosed Acute Myeloid Leukemia (AML) in 2017, intensive chemotherapy (ICT) was the only viable option for achieving remission in fit elderly patients. However…
-
Artikel Jurnal
P066 | FACTORS INFLUENCING MOLECULAR RELAPSE IN FAVORABLE-RISK, INTENSIVELY-TREATED, NPM1-MUTATED ACUTE MYELOID LEUKEMIA
As per 2021 ELN guidelines, for NPM1-mutated AML patients only the end-of-treatment (EOT) MRD is considered a clinically relevant biomarker, with thresholds of qPCR NPM1mut/ABL1% >2% (hereafter defined as NPM1%) and logarithmic reduction relative to diagnosis 2% or LogR2% or LogR2.1% was observed…
-
Artikel Jurnal
DP026 | OUTPATIENT VS INPATIENT MANAGEMENT OF HMA-VEN TREATED PATIENTS: HOSPITALIZATION DURING THE FIRST CYCLE IS NEEDED? A RETROSPECTIVE, MULTICENTRIC EXPERIENCE.
The combined therapy of hypomethylating agents (HMA) and venetoclax (VEN) has become the standard of care for chemotherapy-ineligible acute myeloid leukemia (AML) patients.Despite the lack of evidence, hospitalization is recommended for at least the first cycle of therapy.We retrospectively…
-
Artikel Jurnal
P043 | TRANSPLANT-FREE APPROACHES IN REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A SINGLE CENTRE STUDY
Background. Autologous stem-cell transplantation (ASCT) represents the main approach for refractory classical Hodgkin Lymphoma (HL). Although often curative, this procedure is frequently hindered by short- and long-term toxicities. In recent years, novel drugs such as Checkpoint Inhibitors (CPI)…
-
Artikel Jurnal
DP094 | COMPARING TREATMENT OUTCOMES IN DE NOVO AND SECONDARY AML PATIENTS RECEIVING VENETOCLAX AND HYPOMETHYLATING AGENTS AS FIRST-LINE THERAPY: A MULTICENTER RETROSPECTIVE STUDY
Secondary AML (sAML), defined by a history of antecedent myelodysplastic (MDS) or myeloproliferative (MPN) disease,or presence of MDS-related gene mutations or cytogenetic abnormalities, has a worse prognosis than de novo AML (dnAML) in patients (pts) receiving intensive therapies. Data on sAML…
-
Artikel Jurnal
C060 | UNRAVELING THE AGGRESSIVENESS OF ACCELERATED CLL THROUGH SINGLE-CELL TRANSCRIPTOMICS AND GENOMIC PROFILING
Introduction Accelerated chronic lymphocytic leukemia (aCLL) is a yet understudied entity consisting of CLL with specific aggressive histological features that likely falls in the biological spectrum between CLL and Richter’s transformation (RT). In this study, we aimed to shed light on the…
-
Artikel Jurnal
P015 | FEATURES AND OUTCOMES OF ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA IN RELATION TO BONE MARROW INFILTRATION: AN ITALIAN UNIVERSITY HOSPITAL ANALYSIS
Studies have suggested that the size of the bone marrow neoplastic lymphoplasmacytic infiltrate holds prognostic value for the time to progression from asymptomatic to symptomatic Waldenstrom Macroglobulinemia (WM). We conducted an analysis on 230 patients with WM diagnosed (2005-2025) at the…
-
Artikel Jurnal
DP032 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS PNEUMONIA HAVE AN IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH ACALABRUTINIB AND ZANUBRUTINIB: A MULTICENTRE SEIFEM STUDY.
Infections are a major source of morbidity and mortality in patients (pts) with Chronic Lymphocytic Leukemia (CLL). The aim of our study is to describe in a real-world setting the infectious complications in pts with CLL treated with second generation Bruton’s Tyrosine Kinase inhibitors (BTKis)…
-
Artikel Jurnal
P029 | SECONDARY HYPOGAMMAGLOBULINEMIA IN NON-HODGKIN LYMPHOMAS: INCIDENCE, RISK FACTORS, AND CLINICAL IMPACT
The most frequent form of secondary immunodeficiency (SID) is secondary hypogammaglobulinemia (SAD), commonly caused by B-cell non-Hodgkin lymphomas (NHL) and their treatments. SAD is diagnosed by low serum IgG levels: mild-moderate (4–6 mg/dL) and severe (
-
Artikel Jurnal
DP040 | NOVEL GENETIC VARIANTS AND OLIGOGENIC MECHANISMS IN IDIOPATHIC ERYTHROCYTOSIS: A TARGETED NEXT-GENERATION SEQUENCING APPROACH
Idiopathic erythrocytosis (IE) includes a heterogeneous group of disorders defined by increased red cell mass without secondary causes or known clonal mutations. While advances in molecular diagnostics have uncovered variants in genes related to oxygen sensing, erythropoietin signaling, iron…
-
Artikel Jurnal
C039 | IMPACT OF VENETOCLAX-BASED THERAPIES ON AUTOIMMUNE CYTOPENIAS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL ANALYSIS OF A MULTICENTER STUDY CONDUCTED BY ERIC
Autoimmune cytopenias (AIC) are a typical complication in chronic lymphocytic leukemia (CLL). The impact of venetoclax (ven)-based therapies on CLL-associated AIC is currently largely unknown. The aim of this multicenter study is to retrospectively evaluate in patients receiving ven-containing…